MeiraGTx (MGTX) to Announce Earnings on Thursday

MeiraGTx (NASDAQ:MGTX) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.4583) per share and revenue of $0.70 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

MeiraGTx (NASDAQ:MGTX) last announced its earnings results on Thursday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.04. The firm had revenue of $0.29 million during the quarter, compared to the consensus estimate of $17.00 million. On average, analysts expect MeiraGTx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MeiraGTx Stock Up 2.1%

MGTX opened at $12.55 on Thursday. MeiraGTx has a 52 week low of $6.62 and a 52 week high of $15.35. The stock has a market cap of $1.16 billion, a PE ratio of -8.48 and a beta of 1.23. The business has a 50 day moving average of $11.62 and a 200-day moving average of $9.57.

Insider Buying and Selling

In related news, insider Stuart Naylor sold 27,659 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $14.80, for a total transaction of $409,353.20. Following the sale, the insider directly owned 640,846 shares of the company’s stock, valued at approximately $9,484,520.80. This represents a 4.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alexandria Forbes sold 62,000 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $9.17, for a total transaction of $568,540.00. Following the sale, the chief executive officer owned 1,387,695 shares of the company’s stock, valued at approximately $12,725,163.15. This represents a 4.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 145,659 shares of company stock worth $1,678,453 in the last quarter. Corporate insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On MeiraGTx

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its position in MeiraGTx by 43.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock valued at $31,000 after acquiring an additional 1,466 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of MeiraGTx by 390.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock worth $57,000 after purchasing an additional 7,005 shares in the last quarter. Abel Hall LLC bought a new stake in shares of MeiraGTx in the 4th quarter worth $98,000. Hsbc Holdings PLC lifted its holdings in shares of MeiraGTx by 24.3% during the fourth quarter. Hsbc Holdings PLC now owns 23,792 shares of the company’s stock valued at $189,000 after purchasing an additional 4,649 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new position in shares of MeiraGTx during the fourth quarter valued at $213,000. Institutional investors own 67.48% of the company’s stock.

Analyst Upgrades and Downgrades

MGTX has been the subject of a number of research reports. Piper Sandler increased their price objective on MeiraGTx from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, April 22nd. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of MeiraGTx in a report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MeiraGTx in a research report on Friday, July 17th. Finally, Royal Bank Of Canada increased their price target on shares of MeiraGTx from $25.00 to $26.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, MeiraGTx has an average rating of “Moderate Buy” and an average price target of $26.00.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.